In:
Siberian journal of oncology, Tomsk Cancer Research Institute, Vol. 18, No. 5 ( 2019-11-01), p. 54-60
Abstract:
Because of the high risk of brain metastases from HER2-positive breast cancer, the study of the anticancer activity of drugs used to treat brain tumors, in particular lomustine, is of great importance. In the FVB/N Her-2 transgenic mice bearing HER2-positive breast cancer (BC HER2+), a single oral administration of lomustine at a dose of 50 mg/kg resulted in a significant tumor growth inhibition (up to 96 %, p 〈 0.0001). The tumor growth index (TGI) expressed as a ratio between the areas under the kinetic curves of tumor growth in the study and control groups and amounted to 33 % (p 〈 0.001) indicated the high activity of lomustine. However, the effect of lomustine on intramuscularly transplanted Ehrlich tumor was insignificant (tumor growth inhibition and tumor growth index were 〈 39 % and 68 %, respectively). Lomustine administered orally at a single dose of 50 mg/kg 24 hours after intracranial transplantation of BC HER2+ increased the median survival time up to 30 days in FVB/N mice compared to 21 days in the control group mice (p 〈 0.001). The high therapeutic effect of lomustine in HER2-positive breast cancer mice is likely can be explained by the biological characteristics of this tumor; therefore clinical trials of lomustine for HER2-positive tumors are needed.
Type of Medium:
Online Resource
ISSN:
2312-3168
,
1814-4861
DOI:
10.21294/1814-4861-2019-18-5
DOI:
10.21294/1814-4861-2019-18-5-54-60
Language:
Unknown
Publisher:
Tomsk Cancer Research Institute
Publication Date:
2019
detail.hit.zdb_id:
2693095-X
Permalink